サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413612

T細胞リンパ腫市場：治療法別、エンドユーザー別-2024-2030年の世界予測

T-cell lymphoma Market by Treatment (Chemotherapy, Corticosteroids, Retinoid), End-User (Ambulatory Surgery Centers, Clinics, Hospitals) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 183 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
T細胞リンパ腫市場：治療法別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

T細胞リンパ腫市場規模は2023年に21億6,000万米ドルと推計され、2024年には22億5,000万米ドルに達し、CAGR 4.06%で2030年には28億6,000万米ドルに達すると予測されます。

T細胞リンパ腫の世界市場

主な市場の統計
基準年[2023］ 21億6,000万米ドル
予測年[2024］ 22億5,000万米ドル
予測年 [2030] 28億6,000万米ドル
CAGR（%） 4.06%
T細胞リンパ腫 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはT細胞リンパ腫市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、T細胞リンパ腫市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-T細胞リンパ腫市場の市場規模および予測は？

2-T細胞リンパ腫市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-T細胞リンパ腫市場における技術動向と規制の枠組みは？

4-T細胞リンパ腫市場における主要ベンダーの市場シェアは？

5-T細胞リンパ腫市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • T細胞リンパ腫の普及率が世界中で増加
      • 治療に対する意識を高めるための政府の取り組み
      • ヘルスケアインフラ開発への投資の増加
    • 抑制要因
      • 新興経済諸国におけるT細胞リンパ腫治療の高額な費用と償還の欠如
    • 機会
      • T細胞リンパ腫処理に関する研究開発活動
      • 末梢T細胞リンパ腫（PTCL）の併用療法の進歩
    • 課題
      • 特定の診断特性の欠如
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 T細胞リンパ腫市場治療別

  • 化学療法
  • コルチコステロイド
  • レチノイド
  • 局所療法

第7章 T細胞リンパ腫市場：エンドユーザー別

  • 外来手術センター
  • クリニック
  • 病院

第8章 南北アメリカのT細胞リンパ腫市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のT細胞リンパ腫市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのT細胞リンパ腫市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Acrotech Biopharma, LLC
    • Autolus Therapeutics PLC
    • Bausch Health Companies Inc.
    • Bristol Myers Squibb Company
    • Citius Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genmab A/S
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin Co., Ltd.
    • Macopharma
    • Merck & Co. Inc.
    • Novartis AG
    • Soligenix, Inc.
    • Spectrum Pharmaceuticals Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. T-CELL LYMPHOMA MARKET RESEARCH PROCESS
  • FIGURE 2. T-CELL LYMPHOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. T-CELL LYMPHOMA MARKET DYNAMICS
  • FIGURE 7. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. T-CELL LYMPHOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. T-CELL LYMPHOMA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. T-CELL LYMPHOMA MARKET SIZE, BY RETINOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. T-CELL LYMPHOMA MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. T-CELL LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. T-CELL LYMPHOMA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. T-CELL LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 101. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. T-CELL LYMPHOMA MARKET LICENSE & PRICING
目次
Product Code: MRR-62667ADF93C5

[183 Pages Report] The T-cell lymphoma Market size was estimated at USD 2.16 billion in 2023 and expected to reach USD 2.25 billion in 2024, at a CAGR 4.06% to reach USD 2.86 billion by 2030.

Global T-cell lymphoma Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.16 billion
Estimated Year [2024] USD 2.25 billion
Forecast Year [2030] USD 2.86 billion
CAGR (%) 4.06%
T-cell lymphoma Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-cell lymphoma Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-cell lymphoma Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-cell lymphoma Market, highlighting leading vendors and their innovative profiles. These include Acrotech Biopharma, LLC, Autolus Therapeutics PLC, Bausch Health Companies Inc., Bristol Myers Squibb Company, Citius Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Macopharma, Merck & Co. Inc., Novartis AG, Soligenix, Inc., and Spectrum Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the T-cell lymphoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Chemotherapy
    • Corticosteroids
    • Retinoid
    • Topical Therapy
  • End-User
    • Ambulatory Surgery Centers
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the T-cell lymphoma Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-cell lymphoma Market?

3. What are the technology trends and regulatory frameworks in the T-cell lymphoma Market?

4. What is the market share of the leading vendors in the T-cell lymphoma Market?

5. Which modes and strategic moves are suitable for entering the T-cell lymphoma Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. T-cell lymphoma Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of t-cell lymphoma worldwide
      • 5.1.1.2. Government initiatives to increase treatment awareness
      • 5.1.1.3. Rising investments in healthcare infrastructure development
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of t-cell lymphoma treatment and lack of reimbursement in developing economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Research & development activities regarding t-cell lymphoma treatment
      • 5.1.3.2. Advancements in combination therapies for peripheral T-cell lymphoma (PTCL)
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of specific diagnostic characteristics
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. T-cell lymphoma Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Corticosteroids
  • 6.4. Retinoid
  • 6.5. Topical Therapy

7. T-cell lymphoma Market, by End-User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgery Centers
  • 7.3. Clinics
  • 7.4. Hospitals

8. Americas T-cell lymphoma Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific T-cell lymphoma Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa T-cell lymphoma Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Acrotech Biopharma, LLC
    • 12.1.2. Autolus Therapeutics PLC
    • 12.1.3. Bausch Health Companies Inc.
    • 12.1.4. Bristol Myers Squibb Company
    • 12.1.5. Citius Pharmaceuticals, Inc.
    • 12.1.6. F. Hoffmann-La Roche Ltd.
    • 12.1.7. Genmab A/S
    • 12.1.8. GlaxoSmithKline PLC
    • 12.1.9. Johnson & Johnson Services, Inc.
    • 12.1.10. Kyowa Kirin Co., Ltd.
    • 12.1.11. Macopharma
    • 12.1.12. Merck & Co. Inc.
    • 12.1.13. Novartis AG
    • 12.1.14. Soligenix, Inc.
    • 12.1.15. Spectrum Pharmaceuticals Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing